Promising combo for tough lymphoma cases never got off the ground
NCT ID NCT06767956
First seen Apr 23, 2026 · Last updated May 20, 2026 · Updated 4 times
Summary
This study aimed to test a combination of two drugs, golcadomide and nivolumab, in adults with non-Hodgkin lymphoma that did not respond or returned after CAR-T cell therapy. The goal was to find the safest dose and see if the combination could shrink tumors. However, the study was withdrawn before any participants were enrolled, so no results are available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-HODGKIN LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.